A crucial point for the management of pancreatic ductal adenocarcinoma (PDAC) is the decrease of R1 resections. Our aim was to evaluate the combination of multispectral optoacoustic tomography (MSOT) with fluorescence guided surgery (FGS) for diagnosis and perioperative detection of tumor nodules and resection margins in a xenotransplant mouse model of human pancreatic cancer. The peptide cRGD, conjugated with the near infrared fluorescent (NIRF) dye IRDye800CW and with a transcyclooctene (TCO) tag for future click chemistry (cRGD-800CW-TCO), was applied to PDAC bearing immunodeficient nude mice; 27 days after orthotopic transplantation of human AsPC-1 cells into the head of the pancreas, mice were injected with cRGD-800CW-TCO and imaged with fluorescence-and optoacoustic devices before and 2, 6 and 24 hr after injection, before they were sacrificed and dissected with a guidance of FGS imaging system. Fluorescence imaging of cRGD-800CW-TCO allowed detection of the tumor area but without information about the depth, whereas MSOT allowed high resolution 3 D identification of the tumor area, in particular of small tumor nodules. Highly sensitive delineation of tumor burden was achieved during FGS in all mice. Imaging of whole-mouse cryosections, histopathological analysis and NIRF microscopy confirmed the localization of cRGD-800CW-TCO within the tumor tissue. In principle, all imaging modalities applied here were able to detect PDAC in vivo. However, the combination of MSOT and FGS provided detailed spatial information of the signal and achieved a complete overview of the distribution and localization of cRGD-800CW-TCO within the tumor before and during surgical intervention.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis, which is ascribed to the asymptomatic early phase of the disease and its aggressive tumor biology. The challenge in the management of operable pancreatic tumors is an achievement of R0 resections, that is, complete removal of all tumor nodules. Unfortunately, 80% of pancreatic cancer surgeries are incomplete R1 resections, resulting in a further decreased overall survival.
tumors is restricted to 1 cm deep structures. 3, 4 Furthermore, the strong influence of tissue microenvironment and the light scattering hamper signal quantification. 5, 6 Moreover, the detected fluorescence is projected onto the photographic image of the body surface in two-dimensional (2 D) and attribution to specific organs and structures within the body is not warranted. Nevertheless, planar fluorescence imaging is widely used in preclinical settings and increasingly applied in the clinic as it is noninvasive, easy-to-use, economic and possible in real-time.
Optoacoustic (also called photoacoustic) imaging is an emerging technology, which uses pulsed laser light to excite absorbing molecules. Those molecules undergo thermoelastic expansion leading to the release of acoustic waves. 7, 8 With multispectral optoacoustic tomography (MSOT), tissue can be sequentially illuminated at different wavelengths and images can be processed using spectral unmixing algorithms to distinguish and quantify the contribution of different chromophores in tissue which can be spatially resolved and backprojected to reconstruct a three-dimensional (3 D) image. 9 MSOT delivers anatomical and functional information simultaneously, with a high spatial resolution and up to 5 cm penetration depths, making it suitable for imaging deeper tissues and tumors within the body. 10, 11 Nevertheless, the depth is dependent on the ultrasound frequency, with lower frequencies allowing for greater imaging depth but with a lower spatial resolution. 12 MSOT has been shown to address a number of clinically relevant aspects such as tissue oxygenation or tumor spreading and can potentially overcome a number of other shortcomings in current surgical practice. [13] [14] [15] Both optoacoustic and fluorescence imaging are relying on tumor specific probes. 4, 16 Although there are numerous fluorescent dyes in every desired wavelength, currently, only very few of them are approved for the routine use in patients 17 IRDye800CW is one of the most promising new generation NIR fluorescent dyes, which can be detected by both, fluorescence and optoacoustic imaging and is currently widely tested in clinical trials. 18 Clinical evaluation is possible, as biocompatibility studies of 800CW did not show evidence of toxicity. 19, 20 Here, we decided to use a cyclic arginine-glycine-aspartic acid (cRGD) peptide to target integrins, which are overexpressed in various cancer types and are playing a key role in the early phase of tumor angiogenesis and in tumor cell migration. 21 The cRGD peptide contains only one labeling site for the 800CW dye, in contrast to other targeting biomolecules, like antibodies, which usually contain multiple dye labeling sites and can therefore vary in dye to protein ratios. Therefore, quenching effects from dye-dye interactions caused by multiple labeling are avoided. In the clinic, several RGD constructs are already applied for tumor detection using PET or SPECT. 22 The combination of cRGD and IRDye800CW has already been tested in several preclinical studies, for example, to specifically target integrins in a transgenic mouse model of glioblastoma or to provide high precision delineation of tumor tissue during fluorescence-guided glioblastoma resection. 23 In an orthotopic head and neck cancer model, cRGD-800CW was efficiently combined with a unique handheld spectroscopic device for sensitive detection of integrin overexpression on infiltrating tumor cells for intraoperative visualization of not only invasive tumor margins but also metastatic lymph nodes. 24 In a subcutaneous PDAC model cRGD-800CW allowed for visualization of the tumor up to 24 hr post injection using fluorescence tumor imaging. 25 Here, we used cRGD-800CW-TCO as probe, where a trans-cyclooctene (TCO) tag is already added aiming future pretargeting possibilities. We evaluated cRGD-800CW-TCO as a potential tool for FGS and more importantly as a tool to compare the diagnostic values of planar fluorescence imaging techniques with MSOT for in vivo preclinical imaging of deep seated tumors.
Material and Methods

Probe preparation
The preparation of cRGD-800CW-TCO composed of c[RGDyk] IRDye800CW-(trans-cyclooctente) is extensively described in the Supporting Information Material section.
Animal studies
All animal experiments were performed in accordance with German animal ethics regulations and approved by the local ethics office of Lower Saxony (license no. 33.9-42502-04-13/ 1085). Experiments were performed on athymic nude mice NMRI-Foxn1 nu (Charles River Laboratories), housed in ventilated cages and allowed food and water ad libitum.
What's new?
Pancreatic cancer has poor prognosis, because it initially causes few symptoms, and it's very aggressive. When tumors are surgically removed, microscopic remnants frequently remain, enabling the cancer to return. Advanced imaging techniques, such as fluorescence guided surgery, help surgeons see the boundary between healthy and tumor tissue. Here, the authors demonstrate the effectiveness of multispectral imaging tomography (MSOT) in combination with an integrin-targeting fluorescent probe to collect high resolution 3 D images of pancreatic tumors to be excised. This is the first study showing the unique ability of MSOT to provide detailed information about widespread pancreatic tumors prior to surgery.
The human PDAC cell line AsPC-1 (ATCC, Rockville, MD) was cultivated as described before. 26 For subcutaneous transplantation 1 3 10 6 AsPC-1 cells were resuspended in 100 ml of PBS and transplanted into the left flank under brief isoflurane gas anesthesia (Abbvie, 2%, 0.8 l/min). For orthotopic transplantation 1 3 10 6 AsPC-1 cells were resuspended in 20 ml of PBS and implanted under xylazine (15 mg=kg)/ketamine (75 mg=kg) anesthesia as described before. 26 Mice were sacrificed by isoflurane overdose and cervical dislocation.
Imaging
All in vivo analyses were preceded by native scans (0 hr). Twenty-seven days after transplantation, AsPC-1 tumor-bearing mice received intravenously (i.v.) a single dose of cRGD-800CW-TCO (10 nmol in 100 ml of 0.9% NaCl) and were scanned under isoflurane gas anesthesia (~2%, 0.8 l/min) with the planar fluorescence imaging systems Optix MX2 (ART; time-domain system) and IVIS Spectrum (Perkin Elmer; epi-/trans-illumination system) as well as the small animal optoacoustic imaging system MSOT inVision 256-TF (iThera Medical GmbH) at 2, 6 and 24 hr post injection (p.i.). Mice were sacrificed either 6 hr (n 5 3) or 24 hr (n 5 4) p.i. and one mouse per time-point was frozen (-208C) directly after sacrifice and used for whole body cryosectioning. 27 The other mice were used for fluorescence guided dissection (FGD) with the Artemis system (Quest Diagnostics; epi-illumination) to mimic FGS. 28 Spectrometer measurement. The probe was diluted in a solution of 10% BSA in saline with a final optical density of 0.17. The absorbance spectrum was measured in a 96-well plate between 680 and 900 nm at equidistant intervals of 10 nm using SpectraMax TM M2e (Molecular Devices). The probe spectrum was normalized to the maximum peak absorbance value.
Phantom measurement. The same diluted probe sample was then inserted inside 3 mm wide tubes at the center of a scattering cylindrical agar phantom [1.5% agar and 1% intralipid (Sigma); 2 cm diameter]. MSOT acquisition was performed in five imaging planes (800 lm cross-section) with a 2 mm step size. Images were reconstructed and ROIs were drawn around the insertions to retrieve the mean signal intensities for each measured wavelength (680-900 nm).
In vivo NIRF imaging. In Optix MX2, 730 nm excitation laser and 770 nm LP emission filter were applied for all scans. In vivo whole body scans and ex vivo imaging of organs were performed with 1.5 mm step size and 0.2 sec integration time per scan-point whereas the high-quality scans over the tumor area with 1.0 mm step size and 1.0 sec integration time. Optix 2.02.01 and OptiView 2.01.00 software (ART) were used to acquire and analyze the Optix MX2 data, respectively.
IVIS scans were performed with an excitation filter of 745 nm with 30 nm bandwidth, emission of 800 nm (range 780-840 nm), field of view (FOV) C for the whole-body scans and FOV B for the focused tumour area scans, medium binning. Living Image software 4.4 (Perkin Elmer) was used for IVIS Spectrum image acquisition and analysis.
Optoacoustic imaging and reconstruction. For optoacoustic imaging, the MSOT inVision 256-TF was used. 29 Briefly, a tunable optical parametric oscillator pumped by an Nd:YAG laser provides excitation pulses with a duration of 9 ns at wavelengths from 680 to 980 nm at a repetition rate of 10 Hz with a wavelength tuning speed of 10 ms and a peak pulse energy of 100 mJ at 730 nm. Ten arms of a fiber bundle provide even illumination of a ring-shaped light strip of 8 mm width. For ultrasound detection, 256 toroidally focused ultrasound transducers with a center frequency of 5 MHz (60% bandwidth), organized in a concave array of 2708 angular coverage and a radius of curvature of 4 cm, are used. For scanning, isoflurane anaesthetized mice were covered with ultrasound gel (Parker), gently and tightly wrapped in cling film and placed in a warm water container. Anesthesia was maintained throughout the procedure.
MSOT images were acquired at six different wavelengths: 715, 730, 760, 775, 850 and 900 nm. For each wavelength, 10 consecutive frames were recorded and averaged. Data was fluence-corrected (ms 5 10 cm
21
, ma 5 0.022 cm 21 at 800 nm) to compensate for spectral coloring. Image reconstruction with standard backprojection and spectral unmixing were done using ViewMSOT TM software. Multispectral processing was performed using linear regression on the probe spectrum measured in the phantom. Probe signals were pseudo-colored in jet and overlaid on the corresponding anatomical images (800 nm single wavelength) displayed in gray scale. Maximum intensity images were generated using the 3 D ViewMSOT TM software tools. Any adjustment to brightness, color or contrast has been made to the entire image and applied to all images. For quantification of probe signals, ROI analysis was performed on single image sections of the spectrally unmixed probe signals with the ROI analysis tool of ViewMSOT.
Fluorescence guided dissection. Artemis clinical system for in vivo FGS supported by Artemis Capture Suite 1.1.2 software (Quest Diagnostics) was used for the dissection guidance applying settings of both visible and NIR light. For the visible light of low-pass filter of <640 nm was used. The NIR light was excited with a wavelength of 785 nm, emission was done with a high-pass filter of >808 nm. In addition, reflected excitation light was blocked by a 750-800 nm filter. The raw data could be saved as individual snapshots or a real-time movie for data analysis. Representative movie frames were selected and FIJI software was used to produce color-coded images. 30 Excised organs were first imaged with both, the Optix MX2 and IVIS systems and afterwards fresh frozen and stored at 2808C.
Cryoslicing with fluorescence imaging
The samples were cut at equidistant intervals of 0.5 mm throughout the thoraco-abdominal level. For fluorescence imaging of the cryosections a Leica cryostat (CM 1950, Leica Microsystems, GmbH, Wetzlar, Germany) was retrofitted with a self-made fluorescence imaging system with excitation at 740 nm and emission captured with a 780 nm long pass filter. The exposure time was 2.5 seconds. 27 
Tissue staining
Frozen tissues were sectioned at 2.5 mm slices slice thickness and fixed for 10 min with acetone. For anti-Integrin am staining, slides were incubated for 1 hr with rabbit monoclonal anti-Integrin am antibody (ab179475, Abcam) diluted 1:10.000 in 1% BSA in PBS followed by 30 min incubation with goat ant-rabbit Alexa Fluor 546 (1:400; Mol. Probes). For staining of amb3 integrins, mouse monoclonal antiintegrin am/b3 antibody (sc-7312) was transferred to PBS using a Superdex 75 size-exclusion column (500 ml bed volume, GE Healthcare), brought to pH 8.5 before and directly conjugated with Alexa Fluor 488 for 2 hr slowly rocking in the dark. Slides were incubated for 1 hr with the labeled antiintegrin am/b3 antibody diluted 1:200 in 1% BSA in PBS. Three washing steps with PBS, 5 min each, were performed after each incubation steps. Tissues were mounted with ProLong Gold Antifade Reagent (Thermo Fisher) with DAPI. Hematoxylin and Eosin (HE) staining was performed as described elsewhere. 31 
Tissue imaging and fluorescence microscopy
Tissue imaging was performed on 10 mm tumor cryosections obtained from PDAC bearing mice that received 10 nmol cRGD-800CW-TCO, using the Odyssey flatbed scanner (Licor Biosciences) and analyzed with the respective software. Fluorescence microscopy was performed with an Axiovert 200 M inverted microscope (Carl Zeiss Microscopy GmbH) equipped with a NIR-sensitive ORCA-ER digital camera (Hamamatsu). 708 637.5 nm excitation and 809 640.5 nm emission filter was used for the detection of 800CW, 546 6 6 nm excitation and long pass 590 nm emission filter was used for the detection of Alexa-Fluor 546 fluorescence and 365 6 12.5 nm excitation and 445 6 25 nm emission filter was used for the detection of DAPI.
Image generation and processing were performed with the software AxioVision Rel.4.6 software and FIJI, 30 respectively.
Results
In vitro and in vivo spectral properties of cRGD-800CW-TCO
Spectral features of the cRGD-800CW-TCO-derived signals measured with MSOT in vivo in the subcutaneous tumour were compared to MSOT measurements of the same probe embedded in a phantom and to spectroscopic characteristics of the probe in vitro. As shown in Figure 1a , the in vitro cRGD-800CW-TCO spectrum was clearly red-shifted when compared with MSOT scans in vivo and in the phantom. Based on these results, spectral unmixing was performed in all further in vivo experiments, using the absorption spectrum found with the MSOT phantom instead of using the spectrophotometer absorption spectrum. The binding of cRGD-800CW-TCO and the specificity of the MSOT signals were first confirmed in mice bearing 
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subcutaneous AsPC-1 tumours (n 5 3) 6 hr after i.v. probe injection in comparison to planar fluorescence imaging. In both planar optical imaging systems, Optix MX2 (Fig. 1b) and IVIS (Fig. 1c) , strong probe-derived fluorescence signals were observed over the palpable tumours. Interestingly, NIR fluorescence signals detected with Optix MX2 were almost exclusively colocalized with the tumor region, whereas with the IVIS system additional relatively strong background fluorescence was observed, especially in the area surrounding the subcutaneous tumor and along the spine. Optoacoustic tomography revealed comparably strong probe-derived signals within the subcutaneous tumors but less background signals than planar fluorescence imaging, presumably coming from the remaining cRGD-800CW-TCO circulating in the bloodstream (Fig. 1d) . Notably, the transversal scans obtained with the MSOT system revealed heterogeneous distribution of the probe within the tumor (Fig. 1d ), suggesting areas with a different degree of cRGD-800CW-TCO accumulation.
MSOT allows in vivo 3 D visualization of deeply located tumor nodules in the orthotopic PDAC mouse model
To validate the applicability of cRGD-800CW-TCO as a contrast agent for fluorescence-and optoacoustic imaging of deeply located tumors, an orthotopic mouse model of human PDAC was used in which AsPC-1 cells were transplanted into the head of the pancreas of nude mice. At the time of the imaging experiments-3.5 weeks after the transplantation-all mice had developed nodular primary tumors widely spread within the pancreas. The tumors generally showed invasion into the stomach and duodenum and massive tumor spread to different distant sites and organs adjacent to the pancreas such as the liver, spleen or mesentery as well as growth of a tumor mass at the site of surgical incision (Figs.  2a-2d) .
AsPC-1 tumor-bearing nude mice (n 5 7) were imaged with the OptixMX2, IVIS and MSOT before and 2, 6 and 24 hr after i.v. injection of a single dose of cRGD-800CW-TCO (10 nmol).
As shown in Figure 2e , OptixMX2 detected a strong fluorescence over the upper abdomen, where both, the primary PDAC tumor and the tumor mass at the site of surgical incision are located. The fluorescence intensity was highest at 2 hr p.i., decreased at 6 hr p.i., but was still clearly detectable at 24 hr p.i. Heterogeneous background fluorescence was detectable at all scan time-points, which was presumably due to the presence of the circulating probe as well as a strong fluorescence signals from the excreted probe within the bladder. The highest tumor to background ratio (TBR) of 1.8 6 0.3 was measured with the OptixMX2 at 2 hr p.i. and decreased over time to 1.4 6 0.3 at 6 hr and 1.5 6 0.3 at 24 hr p.i. A comparable fluorescence distribution pattern (Fig. 2f) was obtained with the IVIS system with TBRs of 1.7 6 0.2 at 2 hr p.i., 2.0 6 0.2 at 6 hr p.i. and 2.2 6 0.2 at 24 hr p.i.
We observed that mice, which developed a large tumour mass at the surgical scar at the abdominal wall also showed higher cRGD-800CW-TCO-derived fluorescence intensities (Supporting Information Fig. S2 ). These findings suggest that the epifluorescence signals detected over the abdominal area are the sum of the fluorescence from the probe bound to the primary tumors and to the tumor mass grown at the surgical scar.
Next, we used MSOT (Fig. 3) Using MSOT, we could not only detect a clear accumulation of cRGD-800CW in the primary tumor but also in several deeply located tumor nodules (Fig. 3a) , which were clearly distinguishable from the primary tumor. Interestingly, we detected only very low background signals from the circulating probe, reflected in high TBRs of 29.5 6 0.9 at 2 hr, 33.5 6 0.9 at 6 hr and TBRs of 49.3 6 2.8 at 24 hr p.i.
Furthermore, using MSOT, we could clearly confirm the renal excretion pathway of cRGD-800CW-TCO, which is typical for small molecules: both, MSOT images (Fig. 3a) and biodistribution results (see Supporting Information Material), revealed a strong detection of probe-derived signals in the kidneys (plane 2; green) and in the bladder (plane 3; red dashed line), but not in the liver (plane 1).
cRGD-800CW-TCO enables FGD of PDAC
Finally, FGD was performed in the orthotopic PDAC model with the guidance of the clinical system Artemis, to assess the value of cRGD-800CW-TCO for the delineation of the margins between normal and PDAC tissue during surgery. At both, 6 hr ( Fig. 4a ) and 24 hr (Fig. 4b) after cRGD-800CW-TCO injection, strong fluorescence signals over the central abdomen were detected with the open field camera even through the skin (frame 1). Following median laparotomy and removing the skin, the fluorescence detectable through the peritoneum became more prominent (frame 2). Opening the peritoneum revealed that the fluorescence was mainly located over the primary tumor area (frames 3-5) as well as over the tumor mass at the site of surgical incision (data not shown). In addition, a strong fluorescence was detectable over the kidneys and bladder, especially at 6 hr p.i., which most likely corresponds to excreted cRGD-800CW-TCO. Lower fluorescence was also detectable over organs known to have a high integrin expression such as the intestine and the uterus. As shown in Figure 4c FGS allowed a clear delineation of the tumor margins. In addition, ex vivo imaging shows an increased signal at both, the tumor and scar thereby confirming the findings mentioned above and with MSOT. The real-time images taken before and directly after the resection of the pancreatic tumor tissue, together with stomach and duodenum, clearly confirmed that the resection bed is empty of the tumor-derived fluorescent signals upon removal of the cRGD labeled tissue, with only the background fluorescence remaining (Fig. 4c) .
Ex vivo validation confirms accumulation of cRGD-800CW-TCO in an orthotopic PDAC mouse model
To verify the accumulation of cRGD-800CW-TCO within the tumor and to validate the results from the in vivo fluorescence-and optoacoustic imaging, we performed various ex vivo analyses.
Two mice with orthotopic PDAC were sacrificed and frozen directly after their last scan (one at 6 hr p.i. and one at 24 hr p.i.) followed by cryosectioning of the entire body. Fluorescence distribution in the transversal cryosections with respect to the mouse anatomy was then compared with the signals obtained by spectral unmixing of MIPs of MSOT data. Figure 5 shows representative transversal slices at the level of the bladder, the tumor and the kidneys for the PDAC mouse sacrificed at 6 hr p.i. In both tested mice the ex vivo fluorescence measurements revealed a similar distribution pattern as the optoacoustic signals obtained in vivo with MSOT (Fig. 5, yellow arrows) .
Finally, excised samples of tumor tissue attached to the stomach and liver were cryosliced and analyzed with a flatbed fluorescence scanner before HE staining was performed. As shown in Figures 6a and 6b , strong cRGD-800CW-TCO fluorescence was predominantly found at the tumor margins allowing for a clear delineation of the tumor nodules (Fig. 6a) , with lower but still well detectable fluorescence within the central tumor mass. On a cellular level, costaining of the tumor sections with antibodies targeting different integrins was performed, to visualize the distribution of the in vivo injected probe, cRGD-800CW-TCO, in relation to the target. As shown in Figure 6c , the staining pattern of the anti-amß3 integrin antibody (in blue) showed a highly similar pattern to that of the injected cRGD-800CW-TCO probe (in green). In contrast, anti-am integrin antibody (in red) homogenously stained the tumor tissue, however without any correlation to the cRGD-800CW-TCO binding sites. The same staining pattern was observed on high resolution images (Fig. 6d) .
Discussion
To our knowledge, this is the first study showing the potential and feasibility of MSOT as a preoperative imaging modality for the detection of deep-seated orthotopic pancreatic tumors in mice with an integrin targeting probe. 32 Using cRGD-800CW-TCO as a probe, we were able to distinguish the primary tumor and several small tumor nodules from healthy tissue noninvasively, with high specificity and with notably higher resolution than by planar fluorescence imaging. Finally, during FGD, which we used to mimic PDAC surgery, we not only confirmed the localization of the tumor nodules detected by MSOT but could also clearly delineate tumor margins with high sensitivity.
In the first part of our study, we analysed the spectral characteristics of cRGD-800CW-TCO and found a clear red-shifted absorbance spectrum of the spectrometer compared to the in vitro and in vivo results by MSOT. This shift can be assigned to differences in relaxation times of probe molecules as they are excited with light pulses of different lengths. 33 In vivo, spectral coloring, the phenomenon by which light propagating through tissue undergoes wavelength specific fluence attenuation 34 or interactions with proteins, might occur and cause wavelength shifts. Spectral unmixing of MSOT was performed after fluence correction using a linear regression algorithm and using the spectrum measured from the MSOT phantom to maximize the specificity of the unmixed results for cRGD-800CW-TCO. As this was closely correlated to the spectrum derived from the subcutaneous tumor, we were confident that using the retrieved spectrum was an appropriate choice.
Using planar in vivo fluorescence imaging in cRGD-800CW-TCO injected orthotopic xenotransplants we were able to detect diffuse fluorescence signals over the upper abdomen, indicative of signal emanating from the primary tumor and/or from the tumor mass at the site of surgical incision. This, however, did not allow for the precise localization of particular tumor nodules nor did it contain any information about the depth. In contrast, scanning the same mice with the MSOT resulted in high-resolution cross-sectional images from the abdominal area, which enabled the detection and localization of the primary tumor and several deeply located small tumor nodules. In addition, by applying planar fluorescence imaging we obtained strong background signals, especially at early time-points p.i., which were much lower in MSOT measurements, resulting in about 15-fold higher TBRs. This can be explained by the fact that with planar fluorescence imaging all the fluorescence, which reaches the object surface from different sources and depths after being subjected to absorbance and scattering, is collected and merged on the intensity maps. Consequently, the fluorescence of deeply located tumors appears less intense and more spread. Furthermore, the fluorescence from the circulating probe, especially in the surface-near areas can appear more intense, increasing the background signal and thereby decreasing the TBR. In this context, one advantage of MSOT over planar fluorescence imaging is the possibility to quantify signals in single slices (see Supporting Information), which leads to more reliable TBRs. Nevertheless, similar to fluorescence imaging, MSOT only allows a relative quantification of the signals. In both methods, absolute quantification can only be achieved by a full correction for the absorption, scattering and anisotropy of the tissue, the technology, which is still in its infancy. 35, 36 Other methods such as gamma spectroscopy or mass spectrometry could be considered to be applied in future studies if absolute quantification of signals is needed. Detection of pancreatic tumors with MSOT has previously been described. Various probes have been used before, for example, targeting Syndecan-1 32, 37 or EGFR 38 and all of them allowed a clear and specific detection of probe derived optoacoustic signals over the primary tumors. However, in all these studies, pancreatic tumor cells were orthotopically transplanted into the tail of the pancreas, which resulted in the development of only locally restricted tumors that grew on the left side of the abdomen next to the spleen and close to the body surface and were therefore relatively easy to localize. By contrast, in our study we transplanted PDAC cells into the head of the pancreas, which resulted in the development of nodular primary tumors widely spread within the pancreas and located deep in the abdominal cavity, invading into the stomach and duodenum and accompanied with tumor mass growing at the site of surgical incision as well as multiple abdominal metastasis, as described by us and others. 27, 39 This is a much more relevant model, as in humans about 65% of the pancreatic tumors arise in the head of the pancreas and only 15% in the body and tail. 40 Despite of this much more challenging model, we could clearly detect optoacoustic signals over the spread tumor nodules, showing that MSOT is highly suitable for the detection and discrimination of particularly deeply located and disseminated tumors.
Finally, by performing FGD of cRGD-800CW-TCO injected tumor-bearing mice we could confirm that the signals detected by the fluorescence camera during the surgery revealed similar patterns than those detected with MSOT before surgery. This shows that MSOT can provide a specific overview of the distribution and localization of the fluorescence signal at the tumor sites and therefore represents an ideal complement to the FGS. In contrast to planar fluorescence imaging-which has excellent sensitivity for superficial targets but becomes strongly limited by absorption and scattering of the incident and emitted light with increasing depth-MSOT is not susceptible to the scatter of emitted light. This makes MSOT more sensitive for imaging of deeply located tissue, as confirmed by the higher TBRs obtained with MSOT. Nevertheless, despite the clear advantages over planar fluorescence imaging such as high spatial resolution and increased penetration depth, MSOT still has its limitations. The work flow of MSOT is much slower than that of planar fluorescence imaging and includes, that is, multiwavelength acquisition, reconstruction, spectral unmixing and further 3 D reconstruction, which can require additional postprocessing and makes operation in real-time not always possible.
The development of MSOT instrumentation arose from the need for translational imaging. Although handheld optoacoustic devices are emerging, which can be handled similarly to classical ultrasound scan-heads, the current clinical translation of optoacoustic systems is still restricted to the detection of intrinsic absorbers such as haemoglobin, melanin or lipids or FDA approved unspecific contrast agents. 13, 41, 42 Several clinical trials using MSOT have already been performed, 43 showing a powerful potential of the technique. However, without the availability of clinical available targeted probes, the full translation of optoacoustic imaging to the clinic is limited. Our study may support a progression in this direction.
Overall, we have demonstrated that cRGD-800CW-TCO can be used as a targeted probe to visualize orthotopic PDAC tumors with several optical imaging modalities. The TCO tag within the probe was designed for future therapeutic approaches based on the two step "click chemistry" principle, aiming future pretargeting possibilities with a radiolabel to irradiate left over tumor tissue. This would involve a twostep system with tumor-specific binding of cRGD-800CW-TCO as the first step and the subsequent binding of a small fast-clearing radiolabelled molecule to the TCO tag as the second step of the treatment. Click chemistry via TCO tag has already been shown to improve tumor specificity. 44 Nevertheless, in addition to the signals at the disseminated primary pancreatic tumors, we detected both, fluorescenceand optoacoustic signals at the abdominal wall. We ascribed these signals to the tumor mass developed at the scar of the laparotomy site, as the fluorescence intensity was in accordance with the size of the tumor mass present at the scar.
Furthermore, we detected relatively high background signals from the circulating probe, as well as relatively high fluorescence from healthy tissue with a high cellular turnover such as intestine or uterus. This is not very surprising, as integrins in general orchestrate cell-cell and cell-extracellular matrix adhesive interactions from embryonic development to mature tissue function. In addition, the amb3 integrin, which is the major target for cRGD, is connected with angiogenesis, wound healing and cell migration. 45 We thus cannot exclude that some tissue remodeling processes involving integrins still take place at the scar tissue, which could be a source of part of the cRGD-derived signals over the upper abdomen. Taken together, this indicates that the RGD-targeting probe, although sufficient for the perioperative detection of tumor nodules, is not ideal for the improvement of the specificity of therapeutic approaches. Therefore, for clinical use, the choice of the target-ligand combination should be further optimized.
Altogether, we showed, that MSOT has the unique ability to give an in vivo whole-body 3 D overview of the distribution of the probe and its clinical presurgery application might provide surgeons with information about the tumor distribution and its interactions with the microenvironment and surrounding organs and structures.
